RxDoctor Payments Data

Jean Paul, DO

Family Medicine · Ankeny, IANPI 1932102639

Payments from drug & device makers

$1,101in general payments, 2019–2025

Across 31 payments — averaging $35.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$381
  • AbbVie$244
  • Novo Nordisk$138
  • Harmony Biosciences LLC$125
  • Abbott$49
  • Amgen$47
  • plus $116 from 5 others

What the payments were for

  • Food & beverage$1,101100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,101 in reported general payments places this provider in the 80th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$54,101
Medicare patients
178
Services billed
963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$67,570
XifaxanRifaximin12$41,453
EliquisApixaban42$36,794
JardianceEmpagliflozin30$34,811
TrulicityDulaglutide21$29,499
JanuviaSitagliptin Phosphate21$22,005
TradjentaLinagliptin19$15,447
FarxigaDapagliflozin Propanediol15$12,133
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,850
Gabapentin122$2,310
Levothyroxine Sodium312$2,070
Omeprazole205$1,818
Atorvastatin Calcium258$1,376
Simvastatin223$1,293
Lactulose25$1,166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$138$67,57040 claims
Boehringer IngelheimJardiance, Tradjenta$381$50,25949 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$39$41,45312 claims
Lilly USA, LLCTrulicity$30$29,49921 claims
AstraZenecaFarxiga$12$12,13315 claims
AbbVieSynthroid$244$40915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Ankeny

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →